Compare HLX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | TYRA |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2021 |
| Metric | HLX | TYRA |
|---|---|---|
| Price | $8.73 | $34.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $10.50 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $41.62 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $6.42 |
| 52 Week High | $10.75 | $38.00 |
| Indicator | HLX | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 56.05 |
| Support Level | $6.03 | $30.10 |
| Resistance Level | $10.75 | N/A |
| Average True Range (ATR) | 0.42 | 2.35 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 4.09 | 55.32 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.